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Abstract
There is considerable amount of interest in the immediate treatment of personnel
involved in high risk situations on the battlefield. A novel approach to drug delivery on
the battlefield based on MEMS technology is discussed. By combining three separately
fabricated layers, a single implantable drug delivery device capable of delivering up to
100 mm3 of a vasopressin solution was developed. In vitro release of vasopressin was
observed and the I-V response of the bubble generator was characterized. Results show
that the voltage at the time of release is -11V while the current is -0.35A, giving a power
output of 3.79W. The time to total release of the drug was less than 2 minutes.
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Goal
The goal of this research is to design and fabricate a device which would serve as a pre-
emptive treatment option to hemorrhagic shock for personnel who are involved in high-
risk situations in battle.
Motivation
In the most hostile military environment, military personnel are constantly under enemy
fire. Hemorrhagic shock is a physical state where soldiers have lost too much blood from
inflicted external or internal wounds, leading to a lack of perfusion to the vital organs of
the body. This is a condition that requires immediate treatment on the battlefield, and the
current method of treatment of hemorrhagic shock requires medical personnel to be
present. This would often take too much time or is simply not a viable option in the midst
of battle, causing the condition to worsen, leading to a higher mortality rate. Among other
applications, an implanted device which could be reliably and remotely activated to
dispense a vasoconstrictor immediately following the onset of hemorrhagic shock could
buy medical personnel the time necessary to stabilize the wounded.
Vasopressin
One of the primary candidate drugs to be delivered is vasopressin. Vasopressin is an anti-
diuretic hormone produced naturally by the posterior pituitary gland. Under normal
circumstances, it is secreted when the body is low on water to reduce urine production.
Secretion of vasopressin has also been observed with decreasing blood pressure, however.
A large amount of vasopressin is released in the event of heavy blood loss, causing large
scale constriction of arterioles and increasing the arterial pressure. This ability to
constrict blood vessels makes vasopressin a good candidate to be the first treatment for
hemorrhagic shock, where immediate stemming of blood loss is needed. Although
vasopressin is a naturally produced hormone in the body, not enough of it is produced to
last long enough to allow the soldier to survive until he/she is treated at a hospital.
Design Considerations
Biocompatibility must be the very first feature to be considered, as the device must be
seamlessly integrated by the user. If the body identifies the implant as a threatening
foreign entity, the implant would be attacked by the host's immune system and
complications could ensue. This not only refers to the device as a whole prior to the
release of the drug, but should any part of the device after the release be incompatible
with the body, that material cannot be used as part of the device design. In addition, it is
critical that the implant be as small as possible, as to minimize the intrusiveness of the
procedure.
As an implanted device, the goals are to be able to dispense the drug vasopressin without
any intrusive measures as well as premature release. To be able to deliver the drug
without intrusions, it would require the device to be able to be reliably triggered remotely.
To make this possible, the device design would have to include a signal receptor to
trigger the drug release. To prevent premature release or leakage of the drug prior to the
desired release, hermetic sealing must be ensured during the fabrication of the device.
Using MEMS Technology
An integrated device centered on micro-electrical-mechanical system, or MEMS,
fabrication technologies was created to house and deliver the drug vasopressin. The
ability to use micro-fabrication technologies, such as using photolithography and deep
ion reactive etching, to precisely define salient features of the device, makes it much
smaller than any hand-crafted device could possibly be. In addition, all materials used
throughout the fabrication process - gold, titanium, silicon, silicon nitride, silicon
dioxide - are not known to be hazardous inside humans, satisfying the biocompatibility
criterion of the device. By separating the device into separate layers, parallel processing
of the membrane and resistor layer is made possible.
Device Operation




Fig. 1. Cut-away side view of the schematics of the assembled device, containing all
three separately fabricated layers.
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The complete implantable device consists of the battery and charge pump (or a capacitor),
resistive element layer (MEMS heaters), glass drug encasing layer, and membrane layer
(MEMS gates). The battery and charge pump applies a current through the MEMS
heaters of the device, causing the titanium resistive element to heat up. This heating
causes local boiling of the drug at the bottom of the glass layer. Bubbles form as the drug
boils, increasing the pressure inside the reservoir and causing the membrane layer above
to burst open. As bubbles continue to form, they cause the drug to be propelled out of the
glass encasing layer through the perforation, thereby dispensing the drug into the body.
MEMS Processes
Deposition
1) Sputtering - this is a high-vacuum process where a target metal is bombarded by
an ionized gas (typically Argon) to release metal atoms, allowing them to attach
onto the designated substrate(s) (e.g. silicon wafer(s)) to form a clean and uniform
layer of the metal. The thickness of the metal layers achieved is highly dependent
on the sputtering time, as the RF power of the ionized gas is usually held constant.
2) Plasma-Enhanced Chemical Vapor Deposition (PECVD) - a process where
precursor gases react on the surface of a substrate within a plasma. After the
reaction, the desired product is deposited onto the surface of the substrate. The
reaction rate is limited by temperature, the type of precursor gases used, as well as
the concentrations of the gasses in the reaction chamber.
Photolithography
1) Application of Hexamethyldisilazane (HMDS) - promotes adhesion of photoresist
onto substrate (Si wafer, nitride wafer, etc)
2) Spin Coating - dispenses and spins different types of photoresist onto wafers,
used as either a protective layer in etching processes or to later be defined into
features using photolithography. The thickness of the photoresist layer is
controlled by its viscosity as well as the speed at which the resist is spun onto the
wafer.
a. Thin resist - OCG825. The target thickness when using this resist is
typically -1 micron.
b. Thick resist - AZP4620. The target thickness when using this resist is
typically >7 microns
3) EV1 exposure - using a chromium-glass mask, selective regions of the
photoresist-coated wafer are exposed to UV radiation, causing bonds to break in
the positive photoresist polymer, leaving behind features that can be washed away
using the proper developer. The exposure time can vary anywhere from 2 seconds
to 90 seconds, depending on the resist type and thickness.
4) Development - the exposed wafers are developed using the correct developer to
leave behind desired features exposed and without the protection of photoresist
for further etching. This step typically takes -60 seconds, but again, depends on
the resist type and thickness.
Etching
1) Wet etching - all of the following etches react isotropically:
a. Au Etch (42% KI + 3%I + 55% H20) - used to etch through gold layer
that is not protected by photoresist. This is typically done to define
features such as contacts and micro-wires
b. Ti Etch (TiN 22-7) - used to etch through Titanium layer that is not
protected by photoresist. This is done to define the resistive feature in the
bubble generation layer.
c. Nano-Strip (90% H2SO4 + 5% H2SO 5 + <1% H20 2 + 5% H20) - used to
remove photoresist after its purpose as a protective layer to Au, Ti etch,
RIE, or DRIE is complete
d. Hydrofluoric Acid (HF) Dip (49% HF + 51% H20) - used to remove
native or thermally grown silicon dioxide.
2) Dry Etching - the following etches exhibit anisotropy:
a. Reactive Ion Etching (RIE) - by using chemically reactive plasmas under
near-vacuum pressures and an applied electromagnetic field, different
materials could be selectively etched using RIE. In this project, using a
CF 4-based recipe, the silicon nitride and silicon dioxide layers are etched
from the membrane layer using RIE.
b. Deep Reactive Ion Etching (DRIE) - an extremely anisotropic etching
technique based on the Bosch process, used to etch through whole silicon
wafers. This process allows for aspect ratios of 20:1 or better in silicon,
and is used to isolate the thin silicon nitride windows in the membrane
layer to be the only thing that separates the drug from the body.
Membrane Layer Fabrication
Starting with a single crystal silicon (SCS) wafer, a 5000 A layer of SiO 2 and 2000 A
layer of SiN are deposited by the manufacturer. Prior to Au deposition, 300 A of Ti is
sputtered onto the SiN to enhance the adhesion of the Au layer. A 200 A layer of Au is
then sputtered onto the Ti. Photolithography is performed on the wafers to define and
protect the Au contacts. The excess gold and titanium on the wafers are wet-etched using
Au and Ti etchants consecutively. The next steps are RIE and DRIE of the backside.
Photolithography is again employed to define the regions of the backside of the wafers
that are to be etched. However, this time, the backside features must line up with the
appropriate frontside features before the etching can take place. To facilitate with the
alignment, both the frontside and backside masks have matching alignment marks, shown
in Fig. 2, for the adjustment process.
Fig. 2. Alignment marks used to align the front and backside of the membrane layer
wafers
Once the alignment and exposure steps are complete, RIE is performed on the backside
of the wafers to remove the SiN layer, followed by DRIE to remove the bulk Si. To
remove the excess protective photoresist, the wafers are immersed in Nano-Strip for 30
" I IX~i
minutes. The wafers are then dipped into a 49% HF solution for 2 minutes to remove the
SiO2 layer under the frontside SiN layer. The resulting membrane layer is shown in Fig. 3.
Fig. 3. Cut-away side view of the resulting membrane layer following microfabrication
steps.
Membrane Layer Function
After the processing steps, everything except the frontside SiN layer and Au contacts in
the backside regions not protected by photoresist are gone. The result is a free-standing
SiN membrane layer with gold contacts acting as fuse. The approximately 2000 A SiN
membrane would be easily perforated by the added pressure from the bubbles generated
by the resistor layer, leading to release of the drug from the glass layer.
Once the device is complete, there would be a small current will continuously go across
the frontside Au of the membrane layer. The purpose of the Au layer, again, is to serve as
a fuse. Once the SiN membrane is burst, the gold layer is patterned so that it will follow
suit. When this occurs, the open circuit will be detected and it would signal the opening
of the membrane as well as the release of the drug.
Glass Layer Fabrication
..... . .
The glass layer of the device is the only one which is not microfabricated within the TRL.
Following a simple design, 2.2-mm thick Pyrex 7740 wafers are outsourced to have 2-
mm radius holes precision-drilled through.
Glass Layer Function
With the membrane and resistor layers hermetically sealed above and below it, the glass
serves as the housing for the drug, and the dimensions listed above give an approximate
drug capacity of a little less than 100 mm3. Although the maximum capacity of the device
is often not necessary, the maximum capacity of the device could be easily changed by
altering the diameter of the hole as well as by using Pyrex wafers of different thickness.
Resistor Layer Fabrication
Starting with a oxide-silicon wafer, 300 A of Ti and 200 A of Au are sputtered onto the
frontside oxide, much like previously with the membrane layer, except this time, the Ti is
not only used to help with adhesion of the gold contact, but is also patterned to become
the resistive elements of the devices. Photolithography is performed on the gold layer to
define the contacts, and the excess Au is wet-etched away. A second photolithography is
then performed on the deposited Ti layer to define the resistive elements. Alignment of
the Ti elements to the previously defined Au contacts is crucial in obtaining good ohmic
contact from the resistors. After another session of wet-etch, this time for Ti, the whole
frontside of the wafer is protected by a layer of thin photoresist to prepare for processing
on the backside.
An alignment and photolithography session is performed on the backside to define
locations where the SiO2 and bulk Si would be RIE-ed and DRIE-ed, respectively. The
locations of the etching are aligned with the locations of the Ti resistive elements. The
purpose of this step is to expose the resistors to the drug contained in the glass layer.
During the DRIE step, the wafer is checked occasionally to ensure that the frontside
oxide layer isn't being too over-etched. After DRIE, the wafers are Nano-Stripped for 30
minutes to remove the remaining photoresist and HF-dipped to remove the frontside
oxide layer.
The very thin Ti resistive elements should now be exposed both on the front and backside,
making the wafers extremely delicate. Therefore, immediately after the HF-dip, a thick
layer of SiO2 (~2 microns) is deposited on the frontside using PECVD to give the
resistors structural integrity as well as electrical insulation. The resistor layer is now
ready to be integrated to the drug delivery device, as shown in Fig. 4.
Fig. 4. The first generation resistor layer with the exposed Ti elements. This is the same
cartoon as the lower part of Fig. 1 but upside down.
Resistor Layer Function
When a current is applied to the Au contacts connected to the Ti resistor, the resistor will
quickly heat up, causing the liquid drug nearby to boil. Once a sufficient amount of the
drug has been heated, bubbles will form near the resistor layer. These bubbles will
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increase the pressure on the nitride membrane layer, leading to perforation and beginning
the first stage of drug delivery. As the bubbles continue to form and rise, more and more
of the drug is jettisoned from the glass layer, until almost all the drug is released into the
body.
Second Generation Resistor Layer
The proposed second generation resistors will include changes to cut down processing
steps and complexity of the fabrication, while maintaining the salient features of the first
generation, such as planarity and contact with the drug in the glass layer. The major
difference in design is that the Ti resistor will be in contact with the drug from the
frontside as opposed to through the wafer.
Starting again with an oxide-silicon wafer, the processing steps from the first generation
are mimicked up to the etching of the Ti layer to pattern the resistive elements. From
there, a thick layer of SiOz2 (-2 pm) is deposited onto the frontside of the wafer via
PECVD. At this point, the features already on the wafer - the Au contacts and Ti
resistors - cause the oxide to be deposited in a non-planar fashion, as shown in Fig. 5.
Planarity is such an important feature to all three layers of the device that the first
generation layer design largely accepted the delicately exposed titanium as a necessity to
maintain the planarity of the layer. Therefore, it's important to ensure the same planarity
of the resistor layer in the second design to ensure that all layers are hermetically sealed.
Fig. 5. Existing gold and titanium features on the wafer causes the uniformly-deposited
oxide to be non-planar.
To fix the problem with planarity, a 7-lpm thick layer of thick resist is coated onto the
frontside of the wafer. During post-baking, the photoresist flows to level out the
crevasses created by the gold and titanium features across the whole wafer, leading to a
planar surface on top of the frontside of the wafer. After post-bake, RIE is performed on
the frontside of the wafer. At this stage, it is important to find the right mixture of
reactive gasses in the RIE to ensure a 1:1 selectivity between SiO 2 and the thick
photoresist. Once this is found, the frontside could be uniformly etched until all
photoresist is gone. At this point, the deposited oxide should be successfully planarized
as shown in Fig. 6. Another session of photolithography and RIE are performed on the
frontside to define the Au contacts as well as to provide a via to the Ti resistive elements
for resistive heating of the drug. The wafers are then Nano-Stripped and diced.
Fig. 6. Photoresist is used to achieve a planar surface in the second generation resistor
layer (left). By using a specific CF4 concentration during RIE, a 1:1 selectivity between
the photoresist and SiO 2 was achieved to maintain planarity (right).
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By eliminating DRIE from the fabrication process, the bulk of the Si wafer is kept intact,
and prevents the Ti resistor to be completely exposed during processing. This makes the
second generation resistor layer much more structurally sound compared to the first
without sacrificing planarity of the wafer.
Integration
Once all three layers have been fabricated, they are integrated using UV-activated epoxy.
The result is a one-time drug delivery device in the millimeters size range (Fig. 7). The
goal for the future is to have the integration of the three layers be done through anodic
bonding to ensure enhanced hermetic sealing.
Fig. 7. Size comparison of the first generation device with a standard-sized penny.
Results
Using the first generation devices, the following I-V response was observed for one of
the devices during in vitro release testing, shown in Fig. 8.
The current and voltage recorded at the time of first bubble formation were 0.35A and
11 .0OV, respectively, which translates to a power output of roughly 3.79W. The total
;;; ----------
release of vasopressin





was complete within 2 minutes after the initial application of
resistive elements.
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Fig. 8. I-V response from an in vitro test release. Note the non-ohmic relationship after
the dormation of the first bubble.
Discussion
In vitro release of vasopressin was observed in solution, which is a major milestone in the
project, and shows that the project is on the way to in vivo release testing in the future.
The non-ohmic response observed after the formation of the first bubble could be due to
the decreased heat flow away from the resistive elements into the drug, as the bubble acts
as an obstacle to heat flow. The decreased heat flow would then lead to a localized
overheating of the resistive element, causing the resistivity of the Ti to change. The non-
ohmic response, however, clearly did not prevent bubble formation.
- -- - --
The dimensions of the device should continue to decrease in successive generations as
fabrication techniques and mask designs continue to improve, but will remain constrained
by the volume of the drug delivered. The current direction of the project is to optimize
the power necessary to cause perforation of the membrane layer, with experiments to
determine which conformation of resistive element would be the most effective in
delivering sufficient resistive heating to cause bubble formation. It's also necessary to
ensure that the integrity and functionality of the drug being delivered - in this case,
vasopressin - are not compromised from the resistive heating.
Conclusion
The design and fabrication of a novel implantable drug delivery device were introduced.
The membrane, glass, and resistor layers of the device were shown and discussed. An I-V
characterization of the resistor layer was observed during in vitro release of the drug
vasopressin. Future works will be directed towards eventual in vivo drug release in
animals to test the biocompatibility of the device.
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